A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Inclusion Criteria: 1. Age 18 to 75 years old (inclusive), Female or male 2. Subjects with unresectable locally advanced or metastatic non-small cell lung cancer confirmed by histology or cytology 3. Previously treated by EGFR-TKI or other standard treatment or have not been treated for metastatic setting; 4. At least one measurable tumor lesion according to RECIST v1.1 (enrollment of subjects with only non-target lesions is permitted in Stage IB phase) 5. ECOG performance score of 0-1; 6. Expected survival time ≥ 12 weeks; 7. Adequate bone marrow and organ function 8. Subjects are required to give informed consent for this study prior to the trial and voluntarily sign a written informed consent form. Exclusion Criteria: 1. Subjects with active central nervous system (CNS) metastases. 2. Spinal cord compression not cured by surgery and/or radiotherapy cannot be enrolled. 3. Subjects with uncontrolled tumor-related pain 4. Clinically uncontrollable third space fluid 5. Received antitumor therapy such as chemotherapy within 4 weeks prior to the first dose of study drug; 6. Received \>30 Gy of non-thoracic radical radiation therapy within 4 weeks prior to the first administration of study drug; 7. Major organ surgery or significant trauma within 4 weeks prior to first use of study drug; 8. Concomitant other malignancies ≤ 5 years prior to first dose of study drug; 9. Subjects with a history of interstitial pneumonitis or imaging at screening suggestive of suspected interstitial pneumonitis; or other moderate-to-severe lung disease that severely affects lung function 10. Serious cardiovascular disease 11. Presence of refractory nausea, vomiting, chronic gastrointestinal disease, etc.; subjects with active, known or suspected autoimmune diseases 12. Presence of severe infection within 4 weeks prior to first dose of study drug 13. Subjects with clinically significant bleeding symptoms within 3 months prior to the first dose of study drug 14. Arterial/venous thrombotic events within 3 months prior to the first study dose 15. History of immunodeficiency, including a positive HIV test 16. Presence of active hepatitis B or C; 17. History of severe allergic reactions to other monoclonal antibodies or allergic reactions to any component of the SHR-A2009 product. 18. Known history of alcohol or drug dependence or addiction; 19. Persons with mental disorders or poor compliance;